一例纵向病例报告:重叠睡眠—觉醒表型带来的诊断复杂性
A longitudinal case report illustrating diagnostic complexity among overlapping sleep-wake phenotypes.
一句话摘要
报道一例 45 岁女性,同时存在混合型睡眠呼吸暂停(OSA/CSA)、NREM 异态睡眠(夜惊)、睡眠相关进食障碍、噩梦障碍(有类 RBD 行为但 PSG 无 REM 肌张力缺失)、中枢性嗜睡表型与睡眠—觉醒时相延迟障碍,症状持续二十余年,需多模式治疗;减重(GLP-1 受体激动剂)后睡眠相关进食障碍随之缓解,但因同时改善了 PAP 依从性与用药,无法推断因果,提示 GLP-1 激动剂在该行为中的潜在作用。
为什么重要
用真实病例展示多种睡眠—觉醒表型重叠时的诊断复杂性,提示单一诊断框架下的漏诊风险。
英文摘要原文
The coexistence of multiple primary sleep disorders in a single patient is uncommon and poses significant diagnostic and therapeutic challenges. We report a 45-year-old woman with severe mixed sleep apnea (OSA/CSA), NREM parasomnia (night terrors), sleep-related eating disorder (SRED), nightmare disorder (with RBD like behavior but no REM atonia on PSG), and central hypersomnolence phenotype minimally affected with PAP optimization and delayed sleep-wake phase disorder. Symptoms began more than two decades earlier and included violent dream-enactment behaviors, hypnopompic hallucinations, sleep inertia, and chronic excessive daytime sleepiness (EDS). Treatment required multi-modal therapy. Positive airway pressure therapy successfully treated sleep disordered breathing while pitolisant and solriamfetol produced the most durable improvement in daytime sleepiness. Together melatonin plus clonazepam reduced parasomnia frequency and severity. Several other agents (including prazosin, sodium oxybate, paroxetine, and modafinil) were tried and discontinued for limited benefit or adverse effects. Notably, GLP-1 receptor agonist (GLP-1 RA) therapy for obesity was followed by a substantial weight loss and coincided with resolution of SRED. Because this occurred alongside improved sleep stability, PAP adherence, behavioral adaptation, and medication changes, causality cannot be inferred. The observation may justify further study of metabolic and incretin-related pathways in sleep-related eating behaviors. Overall, this case highlights the complexity of overlapping sleep-wake disorders, the need for individualized pharmacologic sequencing, and a potential emerging role for GLP-1 agonists in SRED.
所属章节
条目编号 P139 · 元数据经 Crossref / Europe PMC 回查